Mannatech, Inc. — FY 2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013; comparisons are to FY 2012. This is an annual report, not a standalone fourth-quarter report, and the provided filing text does not give clear Q4-only results.
Business context
Mannatech sells nutritional supplements, skin-care and weight-management products through independent associates and members in international markets. It reported one operating segment and approximately 245,000 active associates and members at year-end, up from 229,000 in 2012. The company relies heavily on its network-marketing channel and proprietary Ambrotose products.
Financial performance
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Net sales | $177.4 million | $173.4 million |
| Gross profit / margin | $141.3 million / 79.7% | $138.8 million / 80.0% |
| Operating income (loss) / margin | $4.8 million / 2.7% | ($1.0) million / (0.6%) |
| Net income (loss) | $3.2 million | ($1.4) million |
| Diluted earnings (loss) per share | $1.18 | ($0.52) |
| Cash from (used in) operations | $8.6 million | ($1.5) million |
Net sales increased 2.3% reported, but grew 5.2% on a constant-dollar basis, a non-GAAP measure using prior-year exchange rates. Foreign exchange reduced reported sales by about $5 million. Regional sales were North America $82.2 million (down 5.0%), Asia/Pacific $80.3 million (up 13.9%) and EMEA $14.9 million (down 9.1%).
Product sales fell 7.9% to $143.5 million, while pack sales rose 129.8% to $26.2 million. Orders increased 7.4%, but average order value declined to $154 from $172; the company also deferred $5.5 million of revenue for loyalty points. Core Ambrotose products generated $70.8 million, or 40.0% of sales, versus $78.4 million, or 45.2%, in 2012.
Operating expenses declined 2.3% to $136.6 million. Selling and administrative costs fell 9.2% to $33.8 million, and depreciation and amortization declined to $2.1 million from $4.8 million. Commissions and incentives were $75.6 million, or 42.6% of sales. Other expense was $2.0 million, compared with $0.6 million of other income in 2012; 2013 included approximately $1.0 million of Korean customs assessment expense and $1.0 million of foreign-exchange loss.
Liquidity, debt and financial position
Cash and cash equivalents were $20.4 million at year-end, up from $14.4 million; restricted cash totaled $5.8 million. Working capital was $13.5 million, compared with $11.1 million. Total assets were $56.1 million and shareholders’ equity was $23.5 million. Capital-lease obligations had a present value of $1.2 million, including $0.7 million current; the filing reports no long-term debt instruments. Operating cash flow improved to $8.6 million; investing and financing activities used $0.6 million and $1.6 million, respectively. The company suspended dividends in 2009 and reported no 2013 share repurchases.
Outlook, commentary and material matters
- Management stated that cash and expected operating cash flow should fund normal operations and possible international expansion for the next 12 months, while noting this depends on maintaining or growing sales and/or reducing costs. No quantified earnings or revenue guidance was provided.
- Recruitment improved: new independent associates increased 29.9% to approximately 82,200. Management cited compensation-plan changes, revised sign-up packs and a loyalty program launched in 2013.
- The 2013 tax benefit included a $1.0 million benefit connected with settlement of the IRS audit of tax years 2005–2009. The settlement involved $0.8 million of tax deficiency and $0.2 million of interest, paid in 2013. The reported effective tax rate was unusually low at (13.0%); management said it would have been 23.5% excluding the release of uncertain tax positions related to the settlement.
- A Korea customs assessment resulted in approximately $1.0 million of 2013 expense; $0.19 million remained accrued at year-end and was paid in January 2014. A former executive’s gender-discrimination and harassment lawsuit sought damages exceeding $1 million; the company denied the allegations and said the outcome could not be predicted.
- Key risks include associate recruitment and retention, high dependence on Ambrotose sales, regulatory scrutiny of supplements and network marketing, independent-associate claims or misconduct, foreign-exchange exposure, competition, and supplier dependence. Arabinogalactan, an Ambrotose ingredient, had no identified alternative supplier.
- The founder’s consulting agreement ended February 28, 2014 and was not renewed. Separately, the President of International and COO resigned effective January 31, 2014.
Important facts for investors to verify
- Whether the growth in associates, pack sales and Asia/Pacific revenue translates into recurring product sales and improved average order values.
- The effect of loyalty-point revenue deferrals and associated deferred commissions on reported sales, cash generation and future periods.
- Whether operating cash flow and liquidity remain adequate, given $16.1 million of disclosed contractual commitments and contingent legal or tax exposures.
- How sales concentration in Ambrotose products evolves and whether the company can diversify without weakening margins.
- Developments in the former executive lawsuit, Korean customs matters, ongoing tax audits and regulatory compliance across markets.
- The sensitivity of reported results to foreign exchange; the company disclosed that it did not use hedging or derivative instruments.